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perspectives in the management of
rheumatoid arthritis: results from global
physician- and patient-based surveys
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Dario Ponce de Leon13, Anna Maniccia12*, and Ara Dikranian14 for the RA NarRAtive global advisory panelAbstract
Background: In order to better understand the perspectives of patients and physicians regarding the treatment
and management of rheumatoid arthritis (RA), we present and compare results from a patient-based and a
physician-based survey developed by the RA NarRAtive advisory panel.
Methods: The RA NarRAtive initiative is directed by a global advisory panel of 39 healthcare providers and patient
organization leaders from 17 countries. A survey of patients self-reporting a diagnosis of RA and a physician-based
survey, designed by the advisory panel, were fielded online by Harris Poll from September 2014 to April 2016, and
from August 2015 to October 2015, respectively.
Results: We present findings from 1805 patients whose RA was primarily managed by a rheumatologist, and 1736
physicians managing patients with RA. Results confirmed that RA carries a substantial disease burden; half of the
patients surveyed reported stopping participation in certain activities as a result of their disease. While 90% of
physicians were satisfied with their communications with their patients regarding RA treatment, 61% of patients felt
uncomfortable raising concerns or fears with their physician. Of the patients providing responses, 52% felt that
improved dialogue/discussion would optimize their RA management, and 68% of physicians wished that they and
their patients talked more about their RA goals and treatment. Overall, 88% of physicians agreed that patients
involved in making treatment decisions tend to be more satisfied with their treatment experience.
Conclusion: The results of these surveys highlight the impact of RA on patients, and a discrepancy between
patient and physician views on communication. Further research, focused on improving patient–physician dialogue,
shared goal-setting, and treatment planning, is needed.
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Rheumatoid arthritis (RA) is a chronic, progressive, dis-
abling autoimmune disease with an estimated global
prevalence of 0.24% [1]. Over time, a dysregulated
immune-inflammatory process results in damage to the
joints and other organs [2], causing pain, disability, and im-
paired health-related quality of life (HRQoL) [3]. RA is asso-
ciated with a number of comorbidities, such as increased
cardiovascular risk, which can result in higher rates of mor-
bidity and mortality [4]. Consequently, optimum disease
management is important to prevent disease progression
and to improve long-term patient outcomes.
Current clinical guidelines define goals of RA treat-
ment as remission, or low disease activity if remission is
not possible [5, 6]. To meet these goals, guidelines rec-
ommend that patients with RA are initially treated with
conventional synthetic disease-modifying antirheumatic
drugs (csDMARDs). In patients who have an inadequate
response or experience side effects to csDMARDs, escal-
ation to more targeted therapies, either as monotherapy
or in combination with csDMARDs, is recommended
[5–7]. Although newer targeted therapies have greatly
helped to improve the management of RA [8, 9], not all
patients achieve remission, and many would like to
change aspects of their treatment regimen [10, 11].
Due to the chronic nature of RA and the significant im-
pact on HRQoL, the relationship between patients and
their healthcare professionals is important for theFig. 1 Global response to the RA NarRAtive patient and physician surveys.implementation of appropriate treatment strategies [12,
13]. This is reflected in treat-to-target guidelines for the
management of RA, which highlight the importance of
shared decision making between patients and physicians
[14]. Indeed, the first overarching principle in the current
European League Against Rheumatism recommendations
states that treatment of patients with RA “must be based on
a shared decision between the patient and rheumatologist”
[6], and the American College of Rheumatology recom-
mend that “treatment decisions should be made by physi-
cians and patients through a shared decision-making
process taking into account patients’ values, preferences, and
comorbidities” [5]. These decisions relate to all aspects of
the disease, including risks, modalities of disease assess-
ment, decisions on the therapeutic target, development of a
management plan, and discussions on the benefits and risks
of individual therapies. An understanding of both patient
and physician perceptions of RA management could help
foster more effective patient–physician relationships, which
could lead to both increased patient satisfaction and im-
proved treatment outcomes [15, 16].
Here, we present results from a patient-based and a
physician-based survey developed by the RA NarRAtive
global advisory panel. The inclusion of similar questions in
both surveys allowed identification of similarities and differ-
ences in the perspectives of patients and physicians regard-
ing RA treatment and management, while the geographic
coverage of the surveys provided a global perspective.Abbreviation: RA, rheumatoid arthritis
Table 1 Patient demographics and disease characteristics
Patient responders
managed by a
rheumatologista (n = 1805)b
Females, n (%) 1131 (64)
Mean age, years (SD) 51.7 (14.1)
Time since diagnosis, n (%)
< 1 year 95 (5)
1–4 years 490 (28)
5–10 years 597 (34)
> 10 years 582 (33)
Median time since diagnosis, years (SD) 7 (9.8)
Current overall health, n (%)
Good/excellent 550 (31)
Fair 892 (51)
Poor 322 (18)
Self-reported severity of RA, n (%)c
Under control 610 (35)
Not under control 47 (3)
Mild 544 (31)
Moderate to severe 581 (33)
Severe 170 (10)
Abbreviations: RA rheumatoid arthritis, SD standard deviation
aIn Japan, patients managed by an orthopedist were included
b1805 patients were included in the analysis, but not all patients provided
responses to all questions; percentages were calculated based on the number
of responses received
cPatients were permitted to select ≥1 response
Gibofsky et al. Health and Quality of Life Outcomes          (2018) 16:211 Page 3 of 11Methods
Survey design and populations
The RA NarRAtive is an initiative sponsored by Pfizer Inc.
and directed by a global advisory panel of 39 healthcare pro-
viders and patient organization leaders from 17 countries,
with the aim of elevating the role of the patient in the man-
agement of RA [17, 18].
A patient-based survey was fielded by Harris Poll across
16 countries from September 2014 to April 2016. All
patients were ≥ 18 years old and had self-reported that
they had received a diagnosis of RA. In order to compare
findings from the patient and physician surveys, results
from the patient survey are only reported for respondents
currently seeing a rheumatologist (or an orthopedist in
Japan). Most patients were recruited from the Harris Poll
Online Panel, a database of several million people who
have agreed to participate in survey research; most patient
surveys were fielded online (see Additional file 1).
A similar physician-based survey was fielded from
August 2015 to October 2015. The physician questionnaire
mirrored the patient questionnaire where applicable;
questions were added based on research findings and
feedback from the RA NarRAtive advisory panel. Physicians
were asked to provide general information about all
patients with RA for whom they were responsible, not
individual patients. Therefore, no direct links could be
established between responses collected in the patient and
physician surveys. US physicians were recruited, via mail,
from the American Medical Association Physician Master
File. In all other countries, physicians were recruited from
local online panels, using approaches that varied from coun-
try to country. All physicians reported seeing ≥5 patients in
the previous month that they considered to have moderately
to severely active RA.
The surveys were non-interventional and were not
conducted as a clinical study; ethics approval was there-
fore not required.
Additional file 1 includes further details on the survey
design, including some sample survey questions, to-
gether with additional information on the recruitment of
the survey populations.
Analyses of patient and physician surveys
Patient and physician responses were assessed using de-
scriptive statistics, with standard t-tests to assess statisti-
cally significant differences at the 95% confidence level.
Findings for patients from the USA were weighted by
demographic variables (see Additional file 1). All other
responses were not weighted. However, an adjustment
was made to the global 16-country totals to account for
the relative size of each country’s adult population within
the total population of patients and physicians surveyed.
Responses are included for 1805 patients primarily man-
aged by a rheumatologist (or an orthopedist in Japan). Allpercentages are calculated based on a weighted base of
1764, and might not exactly match those derived by manual
calculation due to weighting and/or computer rounding.
Further details on analyses are provided in Additional file 1.
Results
Respondents
Across 16 countries, 4170 patients with RA responded to
the patient survey, of whom 1805 were primarily managed
by a rheumatologist (or orthopedist in Japan) and were in-
cluded in this analysis. A total of 1736 physicians
responded to the physician survey (Fig. 1). Demographic
details, as reported by patients, are given in Table 1. Over-
all, 67% of patients had been diagnosed with RA at least
5 years earlier, 33% self-reported moderate to severe dis-
ease activity, and only 31% described their current overall
health as good/excellent (physicians were not asked to rate
the overall health of their patients). Statistically significant
differences were observed in the percentage of patients
reporting good or excellent health between the USA (50%)
and Taiwan, South Korea, and Spain (all < 10%) (p < 0.05).
In total, 51% of the physicians surveyed were office- or
clinic-based and 22% were mostly hospital- or lab-based.
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month. On average, physicians reported that 29% of
their patients had mildly active disease, 33% had moder-
ately to severely active disease, 17% had severely active
disease, and 15% had uncontrolled disease.
Impact of RA
Fifty-one percent of patients reported stopping participa-
tion in certain activities due to their disease. Thirty per-
cent reported changing jobs (retiring from work
completely, quitting a job, or switching jobs). Addition-
ally, 5% had postponed having children (3% of male and
6% of female patients).
In total, 94% of patients had concerns relating to their
RA. Patients most commonly worried about disease pro-
gression (75%), followed by the impact of the disease on
HRQoL (72%). Treatment-related issues, including
symptoms, treatment failure, exhaustion of treatment
options, and flare-ups as a result of changed medication
were causes for concern amongst 55% of patients,
whereas 30% were worried about treatment access/cost.
The relative importance of these topics was deemed
similar by physicians when asked about the issues they
believe their patients worry about, although
treatment-related concerns and impact on HRQoL were
both the second most commonly selected topics byFig. 2 Goals reported by patients and by physicians for managing RAa. Abb
aPatients were asked, “What are your goals for managing your RA?” and ph
your RA patients’ goals for managing their RA?”. Respondents were permittphysicians (88%). However, physicians were more likely
to indicate that factors (e.g., worsening of RA, possible
disability due to RA, RA will cause problems with job)
were of concern to their patients, than patients were
likely to indicate that concern.
Patient–physician interactions
While 84% of patients were satisfied with the commu-
nication they have with their physician regarding their
RA treatment, 55% indicated a desire to talk to their
physician more about their RA treatment and goals.
Furthermore, 52% felt that improved dialogue or dis-
cussion would help optimize their RA management.
Patient satisfaction with their communication with
their physician varied from country to country. For
example, in the USA, Canada, Argentina, Brazil, and
Romania, over 90% of patients strongly agreed/some-
what agreed that they were satisfied. Also, only 33%
of patients from the USA, but 87% of patients from
South Korea, wanted to talk to their physician more
about their RA treatment and goals (p < 0.05).
In total, 61% of patients felt uncomfortable raising
concerns or fears with their physician. When asked to
provide reasons for this, 32% felt that their physician
knows best and that they should follow what their
physician tells them, and 31% worried that theirreviations: MRI, magnetic resonance imaging; RA, rheumatoid arthritis.
ysicians were asked, “Based on what your patients tell you, what are
ed to select ≥1 response
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that it could affect the quality of care they receive. In
addition, 21% felt that they did not have enough time
to raise their concerns, or did not see their physicianFig. 3 Aspects of RA medication that patients and physicians would most like to
by patients and physicians (b)b. Abbreviation: RA, rheumatoid arthritis. aPatients w
your current RA medication(s)?” and physicians were asked, “Ideally, what would
for RA?”. bPatients were asked, “What are the most important reasons why you d
asked, “Which of the following do you think are the top reasons why your patien
were permitted to select ≥1 response. Patient responses represent a base of patias often as they would like, and 14% felt they lacked
knowledge or understanding. More patients who had
been living with RA for < 5 years reported feeling uncom-
fortable raising their concerns compared with those whochange (a)a, and most frequently cited reasons for non-adherence reported
ere asked, “Ideally, what would you most like to change, if anything, about
you most like to change, if anything, about currently available medications
on’t take your RA medication(s) exactly as prescribed?” and physicians were
ts don’t take their RA medication(s) exactly as prescribed?”. Respondents
ents currently taking prescription medication for their RA (n= 1400)
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57%, respectively; p < 0.05). Interestingly, patients who
felt comfortable raising concerns and fears with theirFig. 4 Criteria for defining treatment success (a)a and treatment failure (b) b,
and by physicians. Abbreviations: RA, rheumatoid arthritis; QoL, quality of life.
does ‘successful’ treatment mean to you?” and physicians were asked, “When
does “successful” treatment mean to you?” bPatients were asked, “When think
physicians were asked, “When thinking about the RA medications that are cur
permitted to select ≥1 response. Patient responses represent a base of patienphysician were more likely to describe their health as
good/excellent than patients who felt uncomfortable
(37% vs. 27%, respectively; p < 0.05).as selected by patients currently receiving prescribed treatment for RA
aPatients were asked, “When thinking about your RA medication(s), what
thinking about the RA medications that are currently available, what
ing about your RA medication(s), what does ‘failure’ mean to you?” and
rently available, what does ‘failure’ mean to you?”. Respondents were
ts currently taking prescription medication for their RA (n = 1400)
Fig. 5 Factors that patients and physicians feel would help them to
more successfully manage RAa. Abbreviation: RA, rheumatoid
arthritis. aPatients were asked, “In thinking about your relationship
with your doctor or healthcare professional, which of the following,
if any, would help you more successfully manage your RA?”.
Physicians were asked, “In thinking about your relationship with your
moderate to severe or severe RA patients, which of the following, if
any, would help you more successfully manage your patients’ RA?”.
Respondents were permitted to select ≥1 response
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their communications with their patients regarding RA
treatment. However, 68% wished that they and their
patients talked more about their RA goals and treatment,
and 66% wished that they could see their patients more
often. The majority of physicians reported discussing
HRQoL issues (93%), side effects/symptoms (93%), RA
treatment (86%), and access/cost-related issues (63%) with
their patients.
Goals for RA management
Nearly all patients surveyed (97%) had goals for man-
aging their disease. The goals reported by patients for
managing RA were similar to the goals reported by
physicians based on their discussions with patients,
with reduction in pain being the option selected by
the highest proportion of both patients and physicians
(Fig. 2). However, some goals were considered differ-
ently by patients and physicians. For example, reduc-
tion in further joint damage and fatigue were
considered to be of higher relative importance in the
patient survey than in the physician survey (Fig. 2).
In contrast, preventing disability, RA remission, and
ability to return to work were considered to be of
higher relative importance in the physician survey
than in the patient survey (Fig. 2). Only 44% of
patients who had goals for managing their RA
reported discussing their progress towards their
treatment goals during every visit with their physician.
RA treatment
Overall, 76% of patients were taking prescription RA
medication, which included pain relief (63%),
csDMARDs (51%), corticosteroids (39%), and biologic
DMARDs (24%). Most patients (81%) who were pre-
scribed treatment for RA responded that they were
satisfied with their treatment. However, 69% reported
that they would ideally like to change something
about their current RA medication. The most com-
monly reported aspects that patients would like to
change were treatment side effects and the number/
frequency of medications. Physician responses regard-
ing the treatment aspects they would like to change
for their patients were similar, although treatment ac-
cess/cost was considered to be of higher relative im-
portance by physicians (Fig. 3a).
In total, 36% of patients reported not taking their
RA prescription medication exactly as prescribed.
Rates of non-adherence were found to vary substan-
tially from country to country, with some differences
being statistically significant (p < 0.05); rates ranged
from 15% in Argentina to 60% in Taiwan (with the
highest adherence rate based on a very small number
of patients). Globally, the most commonly cited reasonsfor non-adherence amongst patients included treatment
side effects, inconvenience, and administration reasons
(Fig. 3b). In the physician survey, similar reasons were
cited (Fig. 3b).
Most (88%) physicians agreed that patients involved in
making treatment decisions tend to be more satisfied with
their treatment experience. Seventy-four percent felt that
patients who are not involved are less likely to adhere to
treatment. Furthermore, setting treatment goals with
patients was considered absolutely essential/very important
by 78% of physicians, and agreement on the treatment plan
was considered to be absolutely essential/very important by
80% of physicians.
Successful treatment was most commonly defined by
patients as a reduction in pain and/or swelling, whereas
physicians most commonly defined treatment success as
the control of disease progression (Fig. 4a). The defini-
tions provided by patients and physicians for treatment
failures were similar and included no improvements/
worsening of symptoms, disease progression, and
reduced HRQoL (Fig. 4b).Future management of RA
Patients most commonly reported that information and
dialogue/discussion are aspects of their interactions
with their physicians that would help them to manage
their RA more successfully (Fig. 5). Amongst physicians,
discussion/dialogue was the most commonly reported
topic for the successful management of RA, followed by
more/longer/additional visits.
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In this paper, we present results from two related
global surveys: one patient-based, and one
physician-based. The surveys were developed by the
RA NarRAtive global advisory panel to better under-
stand the perspectives of both patients and physi-
cians with regards to RA management. We explored
themes relating to the broader impact of RA,
patient–physician interactions, RA treatment goals,
satisfaction with treatment, and RA management.
Questions in the physician survey mirrored those in
the patient survey, where appropriate. Although the
survey populations were independent of each other,
with no direct link between the responses from
patients and those from physicians, this approach
allowed identification of differences in the perspec-
tives of patients with RA and physicians who man-
age and treat patients with RA. The fielding of the
survey in 16 countries also provided a global
perspective, allowing identification of differences in
the views and attitudes of patients and physicians
between countries.
A large proportion of patients reported stopping par-
ticipation in certain activities (51%) or changing jobs
(30%) as a result of their disease. The finding related to
changing jobs is extremely interesting. It suggests that
the introduction of more targeted therapies has not
reduced the impact of RA on work that was reported
before biologics were widely available [19, 20], although
it is important to remember that only 24% of patients
included in this survey were receiving targeted treat-
ment. Furthermore, many patients worried about the
impact of their RA on HRQoL. It is well known that RA
can have a significant impact on patients’ HRQoL [3,
21]. Consistent with this, the results presented here
suggest that some patients may not be receiving optimal
disease management, despite the availability of numer-
ous effective treatments and treatment regimens.
Most physicians (90%) were satisfied with their inter-
actions with patients, while 84% of patients were satis-
fied with communication regarding RA treatment. This
slight disparity is interesting and might reflect a lack of
insight on the part of a small proportion of physicians
regarding their relationship with their patients. Some
physicians wished that treatment and goals could be
discussed in more depth during clinical visits with their
patients, and many wished they could see their patients
more often. Similarly, some patients indicated a desire to
talk to their physician more about their RA goals and
treatment; the proportion of patients varied markedly
from country to country, with 87% of patients from
South Korea, but only 33% of those from the USA,
selecting this option. Over half of the patients respond-
ing acknowledged that improved dialogue or discussionwould help to optimize their RA management. The sur-
veys also showed that patients who described their
current overall health as good/excellent were more likely
to feel comfortable raising their concerns or fears with
their physician than those whose health is not as good.
This might reflect a positive relationship between
patients and physicians, together with a level of confi-
dence and trust in the physician, when patients are in
good health. Taken together, these findings highlight the
importance of effective patient–physician dialogue in the
management of RA, and suggest that patients’ percep-
tions of their relationships with their physician can posi-
tively impact the management of their disease. This is in
line with previous reports suggesting that effective
patient–physician dialogue is important for optimum
RA management [12, 13].
Although newer therapies have enabled physicians to
improve the management of RA, non-adherence per-
sists, and many patients would like to change aspects of
their treatment. Non-adherence rates varied substantially
by country, possibly reflecting social and cultural differ-
ences in the patient–physician relationship between
countries, and highlighting the risks of extrapolating
findings in one country or region to others. Treatment
adherence in patients with RA is known to be low, and
has been shown to vary from 30% up to 80% [22].
Increasing the length of the consultation [23], and
greater involvement with social support groups [24],
could help to improve adherence and, consequently,
treatment efficacy. While a large proportion (81%) of
patients surveyed were satisfied with their RA treatment,
33% considered their RA to be moderate to severe, and
only 35% described their RA as under control. This sug-
gests a disconnect between self-reported treatment satis-
faction and self-described status of disease that might
impact RA management. Also, despite the high propor-
tion of patients reporting that they were satisfied with
their treatment, 69% would ideally like to change some-
thing about their current RA medication. Given the need
to limit respondent burden, detailed questions on the
link between treatment satisfaction and desire for
change were not included in the survey. However, as
side effects and the number/frequency of medications
were the treatment aspects that patients would most like
to change, this might reflect a desire for these aspects to
be improved.
While there were some similarities in the results of the
patient and physician surveys, the relative importance
assigned to issues frequently varied between the two re-
spondent populations. For example, differences in the
goals reported by physicians and patients were identified,
as were differences in the definitions of treatment suc-
cess and treatment failure. Some differences were con-
siderable: 65% of physicians selected being able to return
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only 11% of patients selected this option; respondents
could choose multiple options from the list. Addition-
ally, while 89% of physicians indicated the control of dis-
ease progression as indicative of successful treatment,
only 54% of patients selected this option, and 46% of
physicians selected not meeting treatment goals as a def-
inition of treatment failure, compared with only 25% of
patients.
One challenge may be that terms such as ‘remission’
may mean something different to physicians compared
with patients, and maybe even between different physi-
cians. As in everyday interactions, semantics plays a role
during an open dialogue and discussion. Therefore,
establishing a common meaning for certain words is of
paramount importance. Acknowledging these differences
and challenges could lead to improved patient satisfac-
tion and treatment adherence. This is consistent with
the feeling of most physicians in the current survey that
patients who are involved in making treatment decisions
tend to be more satisfied with their treatment experi-
ence, and those who are not involved are less likely to
adhere to treatment. Differences were also identified in
the topics that patients worry about, and the topics that
physicians believe their patients worry about. Increasing
physician awareness of patients’ fears and concerns may
encourage physicians to probe in more depth when
assessing the disease activity status of their patients and
setting treatment goals.
Shared decision making between physicians and
patients when establishing treatment goals is widely
acknowledged as best practice [5, 15], Furthermore, the
importance of considering the patient’s perspective
regarding treatment is emphasized by the Outcome
Measures in Rheumatology (OMERACT) international
consensus initiative [25]. In line with these and other
recent reports, these surveys emphasize the importance
of taking into account patient needs with respect to
treatment decisions in order to improve patient satisfac-
tion and treatment outcomes [26, 27].
While to our knowledge this is the first report relating
to RA that incorporates the perspectives of both patients
and physicians via the same or similar survey questions,
some of the themes identified are similar to those
reported previously. For example, in a survey of patients
from the Netherlands, the United Kingdom, Austria,
Denmark, France, and the USA, patients reported that
they would like to improve pain, fatigue, independence,
mobility, and physical functioning [28]. Our results are
also consistent with those reported in the Rheumatoid
Arthritis: Insights, Strategies & Expectations (RAISE)
survey, which reported a substantial impact of RA on
HRQoL. As was found here, only a minority of the
patients in the RAISE survey discussed their issues withtheir physician [29]. In a survey of physicians, the level
of agreement with 10 international recommendations for
treating RA was measured, and the highest ranking
statement was ‘the primary target for treatment of RA
should be a state of clinical remission’ [30], which was
also the highest ranking option for successful treatment
selected by physicians in the survey described here. Fur-
ther understanding of the responses from these surveys
will be important to encourage the facilitation of contin-
ued communication between patients and physicians
with the aim of improving outcomes.
As with any patient-based survey, the interpretation of
the patient survey findings were limited by the survey
being strictly self-reported by patients with RA, there-
fore relying on accurate patient recall of disease manage-
ment and their understanding of questions and their
diagnosis of RA. Another possible limitation was the
method for inclusion of respondents. The approach in-
volved including a convenience sample of both patients
and physicians, which introduced the potential for selec-
tion bias. This was predominantly an online survey,
hence patients were likely more computer literate and
active online than the general population and, therefore,
may not be representative of all patients with RA. While
a weighted target approach was used for patients from
the USA in order to balance the sample for patient
demographics, for other countries where weighting targets
were unavailable, the results are only representative of the
individuals sampled and may not be representative of the
general population. A relatively high proportion of
patients who completed the survey reported that they
were not receiving treatment with DMARDs; this could
influence outcomes, particularly if patients were not aware
that their medication is a DMARD. In countries where
some or all patients were recruited from local patient or-
ganizations (South Korea, Taiwan, Hong Kong), there may
have been additional or different types of selection bias
(e.g., membership of the patient organization could indi-
cate patients more engaged in understanding their disease
and improving outcomes than average). Also, in
Argentina, where a portion of the interviews were con-
ducted face to face, interviewer bias and/or social desir-
ability bias may have influenced both willingness to
participate and respondents’ answers to some questions
(e.g., under-reporting of non-adherence). The physician
survey also relied on accurate recall and reporting by phy-
sicians, as well as internet access. Furthermore, although
the surveys were fielded in 16 countries, findings may not
be applicable to all countries/regions due to regional dif-
ferences in the management of RA. Cultural and eco-
nomic differences, as well as differences in healthcare
systems and access to RA treatments between countries,
may have influenced participant responses to this survey.
Geographic differences were observed in several
Gibofsky et al. Health and Quality of Life Outcomes          (2018) 16:211 Page 10 of 11parameters, including patients’ satisfaction with their
communication with their physician and treatment adher-
ence; these might be even greater compared with some
countries not included in this survey. The authors
acknowledge that this survey did not explore all recog-
nized comorbidities and risk factors associated with RA,
such as cardiovascular disease. This reflects the need to
keep the survey to a manageable length, and the focus on
communication and dialogue between physicians and
patients, in order to determine the most important issues
for both groups and ultimately improve the management
of RA.
Conclusion
In conclusion, although patients and physicians placed
similar importance on communication, the survey
results highlighted important disconnects between
patients and physicians, e.g., in regard to the importance
of returning to work as a treatment goal. Geographic
differences were also apparent, with large variations in
the level of medication adherence reported by patients
from different countries. The findings suggest that, at least
in a proportion of cases, improved patient-physician
communication could lead to improved management of
RA. Almost two-thirds of patients in this survey felt
uncomfortable raising concerns or fears with their
physician. Improved dialogue between physicians and
patients may provide the opportunity for patients to more
openly express any expectations or concerns, allowing
physicians to take actions to meet the specific require-
ments of individual patients. Further research on the
reasons for the observed discrepancies between the views
of patients and physicians, and across the various coun-
tries, could help inform efforts to improve interactions
between patients with RA and those managing their
healthcare, and provide guidance or tools to optimize
communication between patients and physicians within
limited consultation times. Overall, greater understanding
and awareness of discrepancies in patient and physician ex-
periences could drive better communication and patient en-
gagement, and possibly lead to improved adherence and
overall patient satisfaction. The RA NarRAtive initiative is
continuing to focus on developing tools and resources that
can bridge these identified gaps to improve patient–physician
dialogue and help improve overall management of RA.
Additional file
Additional file 1 Appendix. Further details on the survey design,
including some sample survey questions, together with additional
information on the recruitment of the survey populations. (DOCX 26 kb)
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